Venture Investing
Investing in Viz.ai | How to Buy Pre-IPO Shares
Learn how to buy Viz.ai pre-IPO shares and review its clinical AI platform, funding, hospital scale, and investment risks.
Add Securities.io to your preferred sources on Google
Securities.io may receive compensation when you use links to products we review. This does not influence our editorial evaluations. We are not a registered investment adviser; this is not investment advice. Read our affiliate disclosure.
Viz.ai — Viz.ai is a private clinical AI company that detects suspected disease in medical imaging and clinical data, coordinates care teams, and helps hospitals and life-sciences partners move patients toward treatment faster.
Private-market status: The company remained private as of September 1, 2026. This article uses primary company materials and independently checked reporting; marketplace indications are not treated as company valuations.
What Is Viz.ai?
Viz.ai began with stroke detection and care coordination, where minutes can determine whether a patient reaches an appropriate specialist in time. The platform now spans more than 50 care pathways across neurology, cardiovascular disease, oncology, and other conditions, using FDA-cleared algorithms and workflow software to connect clinicians around a suspected diagnosis.
By mid-2026, Viz.ai said it was deployed in approximately 2,000 hospitals, covered more than 230 million people, held 13 FDA clearances, and had been evaluated in more than 125 publications. These are company-reported scale indicators. Investors should assess hospital renewal, algorithm performance across populations, integration cost, evidence of improved outcomes, and the economics of life-sciences partnerships.
Viz.ai Products, Projects, and Operating Milestones
Stroke and neurovascular care
Automated detection and mobile coordination help stroke teams review suspected cases, share images, and organize transfers or intervention more quickly.
Cardiovascular pathways
The platform extends into conditions such as pulmonary embolism, aortic disease, and structural heart workflows where fragmented referrals can delay treatment.
Viz Assist multimodal agents
Viz Assist is designed to combine imaging, clinical data, communication, and workflow steps so teams can move from alerting toward guided treatment coordination.
Life-sciences partnerships
Drug and device companies can use disease-finding and care-pathway infrastructure to identify eligible patients and reduce leakage between diagnosis and treatment.
Notable Deployments and Recent Execution
Viz.ai closed 2025 reporting nearly 2,000 hospital deployments and more than 230 million lives covered. It said the healthcare business had become profitable and that the life-sciences operation doubled over the preceding 18 months. Those claims indicate operating leverage, but the company does not publish audited segment revenue or margins.
Recent expansion includes Viz Assist, a multimodal clinical-agent platform, and an oncology alliance with Novartis intended to accelerate diagnosis and precision-care workflows. The strategic opportunity is to become the coordination layer between detection and treatment; the corresponding risk is that clinical evidence, privacy, reimbursement, and workflow adoption must remain strong across each new disease area.
Viz.ai Funding and Valuation
The latest independently supportable financing is $100M Series D (2022). The latest disclosed valuation context is $1.2B (2022). Funding is capital raised or committed; valuation is a negotiated price for a specific security at a specific date. Neither establishes the current value of common shares.
Viz.ai Selected Funding Events
Verified Sep. 1, 2026
Selected disclosed financing, USD; grants, commercial contracts, and marketplace indications excluded.
Funding events 1–2
| Date | Round / Type | Funding Raised | Reported Valuation | Selected Investors | Source |
|---|---|---|---|---|---|
| Apr. 2022 | Series D | $100M | $1.2B | Tiger Global; Insight Partners; others | Viz.ai |
| Mar. 2021 | Series C | $71M | Not disclosed | Scale Venture Partners; Insight Partners; others | Viz.ai |
Preferred shares, common shares, tender offers, debt facilities, and SPV interests can carry different economics. A secondary transaction can provide liquidity to an existing holder without adding operating cash to the company.
Investment Case for Viz.ai
Hospital network scale
A large installed base can support expansion into new care pathways with lower incremental sales and integration cost.
Clinical evidence
Peer-reviewed evidence and FDA clearances can improve physician trust, payer discussions, and defensibility.
Life-sciences revenue
Partnerships can diversify revenue beyond hospital software and monetize faster patient identification for approved therapies.
Multimodal clinical agents
Viz Assist may automate more coordination steps if it remains explainable, secure, and integrated into clinical accountability.
Key Risks
Clinical performance and patient safety
False negatives, false positives, workflow errors, or model drift can delay care and expose patients, clinicians, and the company to harm.
Regulatory and privacy obligations
FDA oversight, HIPAA, data-use agreements, cybersecurity, and evolving AI regulation can slow product changes and increase cost.
Hospital budget pressure
Health systems face long procurement cycles, integration work, and competing capital priorities; pilots do not always convert into enterprise renewals.
Evidence and reimbursement
Adoption may depend on proving that alerts improve outcomes and economics, not merely that an algorithm detects a condition accurately.
Stale valuation context
The $1.2 billion valuation dates to 2022 and may not reflect current growth, preferred terms, public-market multiples, or dilution.
Liquidity and offering structure
Private exposure may come through a fund or SPV with fees and rights that differ from direct Viz.ai shares.
How to Buy Viz.ai Pre-IPO Shares
- Confirm the company is still private. Check official announcements, SEC records, and exchange listings before treating an opportunity as pre-IPO.
- Confirm investor eligibility. Many U.S. private offerings are limited to accredited investors; access varies by jurisdiction.
- Verify the issuer and seller. Confirm the legal entity, capitalization, seller ownership, and whether the company permits the transfer.
- Understand the security. Determine whether the offer is direct stock, a secondary sale, a fund interest, a forward contract, or an SPV.
- Compare rights and full cost. Review share class, preferences, voting, conversion, information rights, fees, carried interest, and settlement costs.
- Plan for illiquidity. Private securities can remain non-transferable for years, and an IPO is never guaranteed.
U.S. investors can review the SEC’s accredited-investor criteria.
Where to Buy Viz.ai Pre-IPO Shares
Availability changes with seller supply, company transfer restrictions, jurisdiction, and investor eligibility. Always verify a live offering rather than assuming shares are available.
MicroVentures
MicroVentures facilitates primary and secondary private-company offerings. Eligibility, minimums, fees, structure, and availability vary by offering; Regulation D opportunities are limited to accredited investors.
View Available Private-Market Opportunities
Viz.ai availability is not guaranteed. Review the specific offering documents before investing.
| Platform | Typical Access Model | What to Verify |
|---|---|---|
| StartEngine Private | Late-stage private-company offerings | Current issuer availability, eligibility, minimum, fees, and vehicle structure |
| Forge Global | Private-company secondary marketplace and brokerage | Seller availability, accreditation, price, share class, and transaction costs |
| EquityZen | Private-company offerings that may use pooled vehicles | SPV terms, fees, minimum, economic rights, and transfer conditions |
| Rainmaker Securities | Broker-assisted private-company transactions | Security source, broker fees, settlement, and company approval |
| EquityBee | Employee option financing and related exposure | Direct ownership versus contractual exposure, fees, and distribution rules |
Viz.ai IPO Outlook
No completed public listing was identified as of September 1, 2026. A late-stage round, executive hiring, audited reporting, or secondary liquidity can support an eventual-IPO thesis, but none substitutes for a filed registration statement and effective listing.
An IPO can be delayed, repriced, replaced by an acquisition, or never occur. Treat it as one possible exit rather than the base case.
Frequently Asked Questions
Is Viz.ai publicly traded?
No. It remains a private company and does not have a public-market ticker.
What is Viz.ai worth?
The latest disclosed valuation context in this research is $1.2B (2022). It applies to a particular date and security and is not a guaranteed current common-share value.
Can retail investors buy Viz.ai stock?
Not on a public exchange. Some eligible investors may find a private offering, but availability, fees, rights, and transfer approval vary.
Will Viz.ai go public?
Possibly, but no guaranteed timetable was identified. Investors should be prepared for a long holding period or no IPO.
Primary and Supporting Sources
- Viz.ai: 2026 ten-year operating update
- Viz.ai: 2025 scale and profitability update
- Viz.ai: Viz Assist launch
- Viz.ai: oncology alliance
- Unite.AI: AI practice-management solutions
Verified September 1, 2026. This article is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Private securities are speculative, may be unavailable in your jurisdiction, and can result in the loss of the entire investment.
